IMAAVY Shows Sustained Disease Control in gMG Patients

IMAAVY (nipocalimab-aahu) has demonstrated sustained disease control for over two years in a broad population of patients with generalized myasthenia gravis (gMG). The extended follow-up period, spanning 120 weeks, revealed consistent clinical improvements and significant reductions in total IgG levels among antibody-positive adult patients. These findings highlight IMAAVY's potential as a long-term therapeutic option for managing gMG. The sustained efficacy and safety profile observed in this study suggest a promising outlook for patients suffering from this chronic autoimmune disorder.